Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Carbapenemase genes among multidrug resistant gram negative clinical isolates from a tertiary hospital in Mwanza, Tanzania
BioMed Research International, Volume 2014, Article 303104, Year 2014
Notification
URL copied to clipboard!
Description
The burden of antimicrobial resistance (AMR) is rapidly growing across antibiotic classes, with increased detection of isolates resistant to carbapenems. Data on the prevalence of carbapenem resistance in developing countries is limited; therefore, in this study, we determined the prevalence of carbapenemase genes among multidrug resistant gram negative bacteria (MDR-GNB) isolated from clinical specimens in a tertiary hospital in Mwanza, Tanzania. A total of 227 MDR-GNB isolates were analyzed for carbapenem resistance genes. For each isolate, five different PCR assays were performed, allowing for the detection of the major carbapenemase genes, including those encoding the VIM-, IMP-, and NDM-type metallo-beta-lactamases, the class A KPC-type carbapenemases, and the class D OXA-48 enzyme. Of 227 isolates, 80 (35%) were positive for one or more carbapenemase gene. IMP-types were the most predominant gene followed by VIM, in 49 (21.59%) and 28 (12%) isolates, respectively. Carbapenemase genes were most detected in K. pneumoniae 24 (11%), followed by P. aeruginosa 23 (10%), and E. coli with 19 isolates (8%). We have demonstrated for the first time a high prevalence of MDR-GNB clinical isolates having carbapenem resistance genes in Tanzania. We recommend routine testing for carbapenem resistance among the MDR-GNB particularly in systemic infections. © 2014 Martha F. Mushi et al.
Authors & Co-Authors
Mushi, Martha F.
Tanzania, Mwanza
Catholic University of Health and Allied Sciences
Uganda, Kampala
Makerere University College of Health Sciences
Mshana, Stephen Eliatosha
Tanzania, Mwanza
Catholic University of Health and Allied Sciences
Imirzalioglu, Can
Germany, Giessen
Justus-liebig-universität Gießen
Germany, Giessen
Partner Site Giessen-marburg-langen
Bwanga, Freddie
Uganda, Kampala
Makerere University College of Health Sciences
Uganda, Kampala
Mbn Clinical Laboratories
Statistics
Citations: 132
Authors: 4
Affiliations: 5
Identifiers
Doi:
10.1155/2014/303104
ISSN:
23146133
e-ISSN:
23146141
Research Areas
Genetics And Genomics
Health System And Policy
Study Design
Cross Sectional Study
Study Locations
Tanzania